Genprex Touts Encouraging Preclinical Data From Lung Cancer Candidate

Genprex Inc GNPX announced that its research collaborators presented preclinical data for the NPRL2 gene (also known as the TUSC4 gene).
The studies used the company's non-viral Oncoprex Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (NSCLC) humanized mouse models.
Data were presented at the 2023 American Association of Cancer Research (AACR) annual meeting.
In the study, humanized mice were treated with NPRL2 gene therapy, immunotherapy Merck's MRK pembrolizumab (Keytruda), or the combination.
An antitumor effect was mediated by NPRL2 treatment, whereas pembrolizumab was ineffective.
A significant antitumor effect was also found in non-humanized NSG mice. However, the antitumor effect was greater in humanized mice, suggesting that the immune response played a role in inducing antitumor activity.
The study data suggest that NPRL2 gene therapy induces antitumor activity on KRAS/STK11 mutant anti-PD1 resistant tumors through DC-mediated antigen presentation and cytotoxic immune cell activation.
Price Action: GNPX shares are up 3.15% at $0.98 on the last check Wednesday.